Show simple item record

dc.contributor.authorIribarren Gómez, Cristina
dc.date.accessioned2022-05-19T07:52:48Z
dc.date.available2022-05-19T07:52:48Z
dc.date.issued2022-05-19
dc.identifier.isbn978-91-8009-789-5 (PRINT)
dc.identifier.isbn978-91-8009-790-1 (PDF)
dc.identifier.urihttps://hdl.handle.net/2077/70931
dc.description.abstractAlterations of the microbiota-host interactions at the mucosal border may be of importance in symptom generation in irritable bowel syndrome (IBS), a disorder of gut-brain interaction. Hence, microbiota-targeted interventions may benefit some patients by beneficially modulating the intestinal microenvironment. This thesis aimed to determine the importance of the intestinal microenvironment for the intestinal immune activity and barrier function in IBS, as well as to assess the effects of human milk oligosaccharide (HMO) supplementation in IBS patients. First, we describe that the IBS patients have a distinct intestinal microenvironment, in particular metabolites, that is linked to bowel habits. Second, we present an in vitro model using patient-derived fecal supernatants and healthy-derived epithelial colonoids for exploring the interactions between the intestinal microenvironment and the epithelial barrier in IBS. Third, we show that a HMO mixture of 2’-Ofucosyllactose and lacto-N-neotetraose (4:1 ratio) (2’FL/LNnT) increases the abundance of bifidobacteria, with no risk of symptom deterioration. Finally, we demonstrate that supplementation with 2’FL/LNnT modulates the gut microbiota, increasing bifidobacteria, and fecal and plasma metabolites, but it does not influence the intestinal immune activity and barrier function. In conclusion, the results of this thesis support the importance of the intestinal microenvironment and the microbiota-host interactions at the mucosal border in IBS, which might be modulated by HMO supplementation. Future studies are warranted to provide a better insight into the cross talk at the mucosal border as well as the mechanisms of action of HMO supplementation for the management of IBS symptoms.en
dc.language.isoengen
dc.relation.haspartI. Ahluwalia B†, Iribarren C†, Magnusson MK, Sundin J, Clevers E, Savolainen O, Ross AR, Törnblom H, Simrén M, Öhman L. A distinct faecal microbiota and metabolite profile linked to bowel habits in patients with irritable bowel syndrome. Cells 2021; 10(6): 1459. https://doi.org/10.3390/cells10061459en
dc.relation.haspartII. Iribarren C†, Nordlander S†, Sundin J, Isaksson S, Savolainen O, Törnblom H, Magnusson MK, Simrén M, Öhman L. Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids. Neurogastroenterology & Motility 2022; 00:e14390 [Published online]. https://doi.org/10.1111/nmo.14390en
dc.relation.haspartIII. Iribarren C, Törnblom H, Aziz I, Magnusson MK, Sundin J, Vigsnæs LK, Amundsen ID, McConnell B, Seitzberg D, Öhman L, Simrén M. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. Neurogastroenterology & Motility 2020; 32(10): e13920. https://doi.org/10.1111/nmo.13920en
dc.relation.haspartIV. Iribarren C, Magnusson MK, Vigsnæs LK, Aziz I, Amundsen ID, Šuligoj T, Juge N, Patel P, Sapnara M, Johnsen L, Sørensen N, Sundin J, Törnblom H, Simrén M, Öhman L. The effects of human milk oligosaccharides on gut microbiota, metabolite profiles and host mucosal response in patients with irritable bowel syndrome. Nutrients 2021; 13(11): 3836. https://doi.org/10.3390/nu13113836en
dc.subjectcolonoidsen
dc.subjectepitheliumen
dc.subjectgut microbiota-host interactionen
dc.subjecthuman milk oligosaccharidesen
dc.subjectintestinal milieuen
dc.subjectirritable bowel syndromeen
dc.subjectmetabolitesen
dc.subjectmicrobiotaen
dc.subjectmucosal borderen
dc.titlelntestinal microenvironment, epithelial barrier interactions and human milk oligosaccharide supplementation in irritable bowel syndromeen
dc.title.alternativeHuman milk oligosaccharides and interactions at the epithelial barrier in IBSen
dc.typetexteng
dc.type.svepDoctoral thesiseng
dc.gup.mailcristina.iribarren.gomez@gu.seen
dc.gup.mailciribarrengomez@gmail.comen
dc.type.degreeDoctor of Philosophy (Medicine)en
dc.gup.originUniversity of Gothenburg. Sahlgrenska Academyen
dc.gup.departmentInstitute of Biomedicine. Department of Medical Microbiology and Immunologyen
dc.gup.defenceplaceTorsdagen den 9 juni, kl. 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborgen
dc.gup.defencedate2022-06-09
dc.gup.dissdb-fakultetSA


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record